Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome.
about
Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib.Identification of potential therapeutic target genes and miRNAs for primary myelofibrosis with microarray analysis.Safety and outcome of allogeneic stem cell transplantation in myelofibrosis.
P2860
Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Primary myelofibrosis: risk st ...... ts with poor clinical outcome.
@ast
Primary myelofibrosis: risk st ...... ts with poor clinical outcome.
@en
type
label
Primary myelofibrosis: risk st ...... ts with poor clinical outcome.
@ast
Primary myelofibrosis: risk st ...... ts with poor clinical outcome.
@en
prefLabel
Primary myelofibrosis: risk st ...... ts with poor clinical outcome.
@ast
Primary myelofibrosis: risk st ...... ts with poor clinical outcome.
@en
P2093
P2860
P356
P1433
P1476
Primary myelofibrosis: risk st ...... nts with poor clinical outcome
@en
P2093
Bruno Deltreggia Benites
Carmino Antonio de Souza
Carolina Silva Costa Lima
Daiane de Almeida
Gislaine Borba Oliveira
Katia Borgia Barbosa Pagnano
Marcia Torresan Delamain
P2860
P304
P356
10.6061/CLINICS/2013(03)OA09
P577
2013-01-01T00:00:00Z